Sanofi Agrees to Buy Dutch Biopharmaceutical Company for EUR308 Million
02 Novembro 2020 - 4:03AM
Dow Jones News
By Joshua Kirby
Sanofi SA said Monday that it has agreed to acquire Dutch
clinical-stage immunotherapy company Kiadis Pharma NV.
The French pharmaceutical company said it had entered into a
definitive agreement to buy all of Kiadis's share capital for a
price of EUR5.45 a share via a public offer. The price represents
an aggregate adjusted equity value of 308 million euros ($358.7
million), and the deal is subject to certain conditions.
Kiadis develops cell-based immunotherapy products for the
treatment of life-threatening diseases, Sanofi said.
"We believe the Kiadis 'off-the-shelf' K-NK cell technology
platform will have broad application against liquid and solid
tumors, and create synergies with Sanofi's emerging immuno-oncology
pipeline, providing opportunities for us to pursue potential
best-in-disease approaches," John Reed, global head of research and
development at Sanofi, said.
Write to Joshua Kirby at joshua.kirby@dowjones.com
(END) Dow Jones Newswires
November 02, 2020 01:48 ET (06:48 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.